{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T17:26:58Z","timestamp":1783963618655,"version":"3.55.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.prp.2025.156098","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T02:39:52Z","timestamp":1751423992000},"page":"156098","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Challenges of CD30 expression and its impact on targeted treatment responses in non-Hodgkin lymphoma: New perspectives for evaluation and validation"],"prefix":"10.1016","volume":"272","author":[{"given":"Yunfei","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianghong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2025.156098_bib1","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/blood.V66.4.848.848","article-title":"The expression of the Hodgkin\u2019s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells","volume":"66","author":"Stein","year":"1985","journal-title":"Blood"},{"key":"10.1016\/j.prp.2025.156098_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1301437","article-title":"Mechanism of action and therapeutic targeting of CD30 molecule in lymphomas","volume":"13","author":"Li","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2025.156098_bib3","doi-asserted-by":"crossref","first-page":"6428","DOI":"10.1158\/1078-0432.CCR-11-0488","article-title":"Brentuximab vedotin (SGN-35)","volume":"17","author":"Katz","year":"2011","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.prp.2025.156098_bib4","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1517\/13543784.2015.1038342","article-title":"Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin\u2019s lymphoma","volume":"24","author":"Merli","year":"2015","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.prp.2025.156098_bib5","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s11864-014-0275-7","article-title":"Role of CD30 targeting in malignant lymphoma","volume":"15","author":"Kumar","year":"2014","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.prp.2025.156098_bib6","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1089\/jir.1998.18.915","article-title":"Analysis of the human and mouse promoter region of the non-Hodgkin\u2019s lymphoma-associated CD30 gene","volume":"18","author":"Croager","year":"1998","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.prp.2025.156098_bib7","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1006\/smim.1998.0156","article-title":"CD30: expression and function in health and disease","volume":"10","author":"Horie","year":"1998","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.prp.2025.156098_bib8","doi-asserted-by":"crossref","first-page":"8731","DOI":"10.3390\/ijms24108731","article-title":"CD30 expression and its functions during the disease progression of adult T-cell leukemia\/lymphoma","volume":"24","author":"Nakashima","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2025.156098_bib9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.critrevonc.2017.02.021","article-title":"Potential application and prevalence of the CD30 (Ki-1) antigen among solid tumors: a focus review of the literature","volume":"113","author":"Berger","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.prp.2025.156098_bib10","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/modpathol.2010.224","article-title":"Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis","volume":"24","author":"Sotlar","year":"2011","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.prp.2025.156098_bib11","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1182\/blood.V96.13.4307","article-title":"Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells","volume":"96","author":"Mir","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.prp.2025.156098_bib12","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.prp.2025.156098_bib13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1158\/1078-0432.CCR-12-0290","article-title":"Brentuximab vedotin","volume":"19","author":"Deng","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2025.156098_bib14","first-page":"1","article-title":"Advances in targeted therapy for malignant lymphoma","volume":"5","author":"Wang","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.prp.2025.156098_bib15","doi-asserted-by":"crossref","first-page":"374","DOI":"10.4143\/crt.2019.198","article-title":"Efficacy of brentuximab vedotin in relapsed or refractory high-CD30\u2013expressing non-Hodgkin lymphomas: results of a multicenter, open-labeled phase II trial","volume":"52","author":"Kim","year":"2020","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.prp.2025.156098_bib16","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1200\/JCO.2014.60.3787","article-title":"Results of a phase II trial of brentuximab vedotin for CD30 + cutaneous T-cell lymphoma and lymphomatoid papulosis","volume":"33","author":"Duvic","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2025.156098_bib17","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"ALCANZA study group, Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.prp.2025.156098_bib18","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.prp.2025.156098_bib19","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.3390\/cells12131783","article-title":"The polyvalent role of CD30 for cancer diagnosis and treatment","volume":"12","author":"Dumitru","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.prp.2025.156098_bib20","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/oncolo\/oyac137","article-title":"Response to brentuximab vedotin by CD30 expression in non-hodgkin lymphoma","volume":"27","author":"Jagadeesh","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.prp.2025.156098_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/nrclinonc.2014.159-c1","article-title":"CD30-targeting immunoconjugates and bystander effects","volume":"12","author":"Masuda","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.prp.2025.156098_bib22","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.prp.2025.156098_bib23","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/17474086.2021.1955344","article-title":"The expression of CD30 and its clinico-pathologic significance in peripheral T-cell lymphomas","volume":"14","author":"Karube","year":"2021","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.prp.2025.156098_bib24","doi-asserted-by":"crossref","first-page":"79","DOI":"10.5858\/arpa.2021-0270-OA","article-title":"Best practices in CD30 immunohistochemistry testing, interpretation, and reporting: an expert panel consensus","volume":"147","author":"Gru","year":"2023","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.prp.2025.156098_bib25","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1182\/blood-2007-06-097014","article-title":"Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30","volume":"110","author":"Oflazoglu","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.prp.2025.156098_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.85","article-title":"Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions","volume":"7","author":"van der Weyden","year":"2017","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.prp.2025.156098_bib27","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hon.2437_65","article-title":"Brentuximab vedotin vs physician\u2019s choice in Ctcl patients from the phase 3 Alcanza study: analysis of outcomes by Cd30 expression","volume":"35","author":"Kim","year":"2017","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.prp.2025.156098_bib28","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jid.2017.11.035","article-title":"Variability in the expression of immunohistochemical markers: implications for biomarker interpretation in cutaneous T-cell lymphoma","volume":"138","author":"Rahbar","year":"2018","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.prp.2025.156098_bib29","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/1535-7163.MCT-23-0118","article-title":"Brentuximab vedotin\u2013driven microtubule disruption results in endoplasmic reticulum stress leading to immunogenic cell death and antitumor immunity","volume":"23","author":"Heiser","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.prp.2025.156098_bib30","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1158\/1078-0432.CCR-09-2069","article-title":"Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate","volume":"16","author":"Okeley","year":"2010","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.prp.2025.156098_bib31","doi-asserted-by":"crossref","first-page":"30523","DOI":"10.18632\/oncotarget.8864","article-title":"CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro","volume":"7","author":"Hansen","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2025.156098_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.698503","article-title":"CD30-positive extracellular vesicles enable the targeting of CD30-negative DLBCL cells by the CD30 antibody-drug conjugate brentuximab vedotin","volume":"9","author":"Lobastova","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.prp.2025.156098_bib33","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","article-title":"Phase II investigator-initiated study of brentuximab vedotin in mycosi s fungoides and s\u00e9zary syndrome with variable CD30 expression level: a multi-institution collaborative project","volume":"33","author":"Kim","year":"2015","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.prp.2025.156098_bib34","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/PAS.0000000000000571","article-title":"CD30 expression by B and T cells: a frequent finding in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma-not otherwise specified","volume":"40","author":"Onaindia","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.prp.2025.156098_bib35","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/his.13647","article-title":"Interobserver variation in CD30 immunohistochemistry interpretation; consequences for patient selection for targeted treatment","volume":"73","author":"Koens","year":"2018","journal-title":"Histopathology"},{"key":"10.1016\/j.prp.2025.156098_bib36","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1097\/PAS.0000000000001041","article-title":"The use of central pathology review with digital slide scanning in advanced-stage mycosis fungoides and s\u00e9zary syndrome: a multi-institutional and international pathology study","volume":"42","author":"Gru","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.prp.2025.156098_bib37","doi-asserted-by":"crossref","DOI":"10.1097\/PAS.0000000000001368","article-title":"Practical approaches on CD30 detection and reporting in lymphoma diagnosis","volume":"44","author":"Xu","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.prp.2025.156098_bib38","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3892\/ol.2012.1034","article-title":"Simultaneous cytomorphological and multiparameter flow cytometric analysis of ALK-positive anaplastic large cell lymphoma in children","volume":"5","author":"Shen","year":"2013","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.prp.2025.156098_bib39","first-page":"228","article-title":"The standardization of immunohistochemical detection and interpretation of CD30 expression in lymphomas","volume":"33","author":"C.-P.L.P.E. Group","year":"2023","journal-title":"China Oncol."},{"key":"10.1016\/j.prp.2025.156098_bib40","article-title":"The spectrum of intestinal mature T- and NK-cell neoplasms in a tertiary center in Taiwan with a high frequency of perforation","volume":"240","author":"Wang","year":"2022","journal-title":"Pathol. Res. Pr."},{"key":"10.1016\/j.prp.2025.156098_bib41","article-title":"B-cell lymphoma: advances in pathogenesis, diagnosis, and targeted therapies","volume":"271","author":"Patil","year":"2025","journal-title":"Pathol. Res. Pr."},{"key":"10.1016\/j.prp.2025.156098_bib42","article-title":"Fibrin-associated large B-cell lymphoma arising in a cystic lymphangiomatous lesion of the adrenal gland: A case report and overview of the entity","volume":"270","author":"Kircher","year":"2025","journal-title":"Pathol. Res. Pr."},{"key":"10.1016\/j.prp.2025.156098_bib43","first-page":"1","article-title":"Clinical roundtable monograph: CD30 in lymphoma: its role in biology, diagnostic testing, and targeted therapy","volume":"12","author":"Sotomayor","year":"2014","journal-title":"Clin. Adv. Hematol. Oncol. HO"},{"key":"10.1016\/j.prp.2025.156098_bib44","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/blood-2014-07-584953","article-title":"Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels","volume":"124","author":"Bossard","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.prp.2025.156098_bib45","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.prp.2025.156098_bib46","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/17474086.2017.1270202","article-title":"Diagnostic, prognostic and therapeutic role of CD30 in lymphoma","volume":"10","author":"Pierce","year":"2017","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.prp.2025.156098_bib47","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.3324\/haematol.2022.280840","article-title":"Pathology review identifies frequent misdiagnoses in recurrent classic Hodgkin lymphoma in a nationwide cohort: implications for clinical and epidemiological studies","volume":"108","author":"Boot","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.prp.2025.156098_bib48","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2011-05-351346","article-title":"EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma*","volume":"118","author":"Kempf","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.prp.2025.156098_bib49","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/blood-2014-09-598763","article-title":"Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed\/refractory DLBCL with variable CD30 expression","volume":"125","author":"Jacobsen","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.prp.2025.156098_bib50","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/his.14910","article-title":"CD30 expression is frequently decreased in relapsed classic Hodgkin lymphoma after anti-CD30 CAR T-cell therapy","volume":"83","author":"Marques-Piubelli","year":"2023","journal-title":"Histopathology"},{"key":"10.1016\/j.prp.2025.156098_bib51","article-title":"Multiplex immunohistochemistry and immunofluorescence: a practical update for pathologists","volume":"36","author":"Harms","year":"2023","journal-title":"Mod. Pathol. Off. J. US Can. Acad. Pathol. Inc."},{"key":"10.1016\/j.prp.2025.156098_bib52","article-title":"In situ characterization of follicular helper CD4 T cells using multiplexed imaging","volume":"11","author":"Ioannidou","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2025.156098_bib53","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/cyto.b.21940","article-title":"Multicentric MFI30 study: standardization of flow cytometry analysis of CD30 expression in non-Hodgkin lymphoma","volume":"100","author":"Debliquis","year":"2021","journal-title":"Cytom. B Clin. Cytom."},{"key":"10.1016\/j.prp.2025.156098_bib54","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3960\/jslrt.21019","article-title":"Better method for detection of CD30: immunohistochemistry or flow cytometry?","volume":"61","author":"Higashi","year":"2021","journal-title":"J. Clin. Exp. Hematop"},{"key":"10.1016\/j.prp.2025.156098_bib55","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1080\/10428194.2016.1256481","article-title":"Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry","volume":"58","author":"Bartlett","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.prp.2025.156098_bib56","doi-asserted-by":"crossref","first-page":"5264","DOI":"10.3390\/cancers14215264","article-title":"Deep learning approaches in histopathology","volume":"14","author":"Ahmed","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2025.156098_bib57","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1136\/jcp-2022-208344","article-title":"Automatic CD30 scoring method for whole slide images of primary cutaneous CD30+ lymphoproliferative diseases","volume":"76","author":"Zheng","year":"2023","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.prp.2025.156098_bib58","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00428-024-03764-1","article-title":"Loss of or decrease in CD30 expression in four patients with anaplastic large cell lymphoma after brentuximab vedotin-containing therapy","volume":"484","author":"Kaimi","year":"2024","journal-title":"Virchows Arch."},{"key":"10.1016\/j.prp.2025.156098_bib59","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/cup.12797","article-title":"Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding","volume":"43","author":"Al-Rohil","year":"2016","journal-title":"J. Cutan. Pathol."},{"key":"10.1016\/j.prp.2025.156098_bib60","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1182\/blood-2015-03-637728","article-title":"Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis","volume":"126","author":"Blatt","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.prp.2025.156098_bib61","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1021\/ac101065b","article-title":"Multiplexed detection and characterization of rare tumor cells in Hodgkin\u2019s lymphoma with multicolor quantum dots","volume":"82","author":"Liu","year":"2010","journal-title":"Anal. Chem."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033825002912?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033825002912?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T22:38:57Z","timestamp":1762295937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033825002912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":61,"alternative-id":["S0344033825002912"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2025.156098","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges of CD30 expression and its impact on targeted treatment responses in non-Hodgkin lymphoma: New perspectives for evaluation and validation","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2025.156098","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a92025 Takeda (China) International Trading Co. Ltd. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"156098"}}